RAD9B: A Potential Drug Target and Biomarker (G144715)

Target Name: RAD9B

NCBI ID: G144715

RAD9B

RAD9B: A Potential Drug Target and Biomarker

RAD9B (RAD9 homolog B) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell growth and has been involved in the development of various diseases, including cancer. RAD9B is a highly conserved gene that is located on chromosome 16 and has been annotated with 19 known protein coding genes and 43 known RNA binding proteins.

History of RAD9B

The discovery of RAD9B dates back to the late 1980s when researchers identified a gene that was highly conserved across various species, including humans. The gene was named RAD9B and its function was not well understood.

Over the years, researchers have made significant progress in the characterization of RAD9B. They have identified that RAD9B is a highly conserved gene that is involved in the regulation of cell growth, cell differentiation, and apoptosis. RAD9B is a positive regulator of cell growth and has been shown to promote the growth of various cell types, including cancer cells.

In addition, researchers have also identified that RAD9B is involved in the regulation of cell apoptosis. They have shown that RAD9B can induce apoptosis in various cell types and that this process is regulated by various factors, including DNA damage, nutrient deprivation, and exposure to chemotherapy drugs.

Potential Drug Target

RAD9B has been identified as a potential drug target due to its involvement in the regulation of cell growth and apoptosis. Drugs that can inhibit the activity of RAD9B have been shown to have therapeutic potential in various diseases, including cancer.

One of the main reasons for the potential of RAD9B as a drug target is its conserved nature. The fact that RAD9B is highly conserved across various species makes it easier to identify potential drug targets. Additionally, the fact that RAD9B is involved in the regulation of cell growth and apoptosis makes it a likely candidate for drugs that can inhibit these processes.

Another potential drug target for RAD9B is its involvement in the regulation of cell differentiation. RAD9B has been shown to regulate the differentiation of various cell types, including cancer cells. This suggests that drugs that can inhibit RAD9B activity may have therapeutic potential in diseases such as cancer.

RAD9B as a Biomarker

RAD9B has also been identified as a potential biomarker for various diseases, including cancer. The fact that RAD9B is highly conserved across various species makes it a potential candidate for use as a biomarker. Additionally, the fact that RAD9B is involved in the regulation of cell growth and apoptosis makes it a likely candidate for use as a biomarker for diseases that are characterized by these processes, such as cancer.

One of the main advantages of using RAD9B as a biomarker is its ability to be easily measured and detected. This is because RAD9B is a non-coding RNA molecule and can be easily isolated and quantified. Additionally, the fact that RAD9B is highly conserved across various species makes it a potential candidate for use as a biomarker that can be used across different species.

Conclusion

In conclusion, RAD9B is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its conserved nature and involvement in the regulation of cell growth and apoptosis make it a promising candidate for drug development. Additionally, the fact that RAD9B is a potential biomarker for various diseases makes it a promising tool for the diagnosis and treatment of these diseases. Further research is needed to fully understand the potential of RAD9B as a drug target and biomarker.

Protein Name: RAD9 Checkpoint Clamp Component B

The "RAD9B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD9B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets